Remove topics final-written-decisions
article thumbnail

The First Post-IPR Director Reviews are Denied

Patently-O

One of the topics to be discussed at tomorrow’s PPAC meeting is USPTO operations following the Supreme Court’s 2021 Arthrex decision. In Arthrex , the Supreme Court created an additional layer of review by the PTO Director in Inter Partes Review (IPR) proceedings following a PTAB final written decision.

Patent 91
article thumbnail

[Webinar] Federal Circuit Appeals from the PTAB and ITC: Summaries of Key 2022 Decisions - February 2nd, 1:00 pm - 2:00 pm EST

JD Supra Law

Topics of the featured intellectual property cases include: exclusion of expert testimony, the ITC’s ability to enforce consent orders, estoppel by IPR final written decisions, standing to challenge PTAB decisions on appeal, obviousness in light of overlapping ranges in the prior art, and settlements of IPRs before.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

[Webinar] 2022 PTAB Year in Review: Analysis and Trends - February 28th, 1:00 pm - 2:00 pm EST

JD Supra Law

Topics include: the Director’s 2022 Fintiv guidance, PTAB discretionary denial, the use of applicant admitted prior art (AAPA) in PTAB proceedings, the Director Review process in light of Arthrex, estoppel triggered by final written decisions, misconduct before the PTAB, and a review of newly designated precedential and informative PTAB decisions.

Art 52
article thumbnail

PTAB Updates and Expands the Director Review Process and Offers Transparency in Ex parte Appeals

LexBlog IP

After the Supreme Court’s decision in United States v. the Patent Office implemented an interim process for the Director to review Patent Trial and Appeal Board decisions in AIA trials. Most decisions don’t implicate these instances, but aggrieved parties will of course argue decisions in their cases do.

article thumbnail

Supreme Court on Patent Law for October 2022

Patently-O

Leading the pack are three cases focusing on “Full Scope” Enablement & Written Description. Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Kite Pharma, Inc. ,

article thumbnail

Federal Circuit Rules on Inventor-as-Lexicographer Definitions and the Proper Scope of Reply and Sur-Reply Briefing Following Patent Owner Responses to IPR Institution Decisions

Intellectual Property Law Blog

The Board issued its final written decision determining claim 3 to be unpatentable as obvious over Tayloe in combination with TI Datasheet (another prior art reference). and finally, the “refer to” language in [5.] ParkerVision, Inc., Katherin K. Vidal, Under Secretary of Commerce for IP and USPTO Director No.

Inventor 130
article thumbnail

Seeing Clearly: Article III Standing of IPR Judicial Review

Patently-O

Article III standing remains a hot topic at all levels of federal litigation and across many different areas of law. With surgery as the only viable course of treatment, Cloudbreak Therapeutics created a topical application of multikinase inhibitors to provide a non-surgical treatment to prevent recurring tumors, which is recognized in U.S.

Art 49